C

    Creative Medical Technology Holdings Inc (CELZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.13
    -0.01 (-0.88%)

    Market Cap: $7.52M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(10/19)
    Avg Surprise
    -98.86%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.24 - $-0.24
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.40-66.7%
    60d ago$-0.40-66.7%
    30d ago$-0.23+4.2%
    7d ago$-0.24+0.0%
    Current$-0.24
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.16 - $-0.16
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.24---
    Jun 26
    		$-0.41$-0.39-5.13%Miss+14.6%
    Mar 26
    		$-0.38$-0.39+2.56%Beat+54.2%
    Dec 25
    		$-0.80$-0.37-116.22%Miss+28.6%
    Sep 25
    		$-0.48$-0.48+0.00%Beat+36.0%
    Jun 25
    		$-0.48$-0.63+23.81%Beat+56.8%
    Mar 25
    		$-0.83$-0.52-59.62%Miss-13.7%
    Dec 24
    		$-1.12$-0.63-77.78%Miss+5.9%
    Sep 24
    		$-0.75$-0.85+11.76%Beat+26.5%
    Jun 24
    		$-1.11$-0.84-32.14%Miss-42.3%
    Mar 24
    		$-0.73$-1.15+36.52%Beat-4.3%
    Dec 23
    		$-1.19$-1.13-5.31%Miss-1600.0%
    Sep 23
    		$-1.02$-0.86-18.60%Miss-45.7%
    Jun 23
    		$-0.78$-0.83+6.02%Beat+61.0%
    Mar 23
    		$-0.70$-1.00+30.00%Beat+61.1%
    Dec 22
    		$-0.07$-0.07+0.00%Beat+98.3%
    Sep 22
    		$-0.70$-1.30+46.15%Beat+6.7%
    Jun 22
    		$-2.00$-1.50-33.33%Miss-60.0%
    Mar 22
    		$-1.80$-2.30+21.74%Beat-116.1%
    Dec 21
    		$-4.16$-0.23-1708.70%Miss+87.0%
    Sep 21
    		$-0.75N/AN/ABeat-635.7%
    Jun 21
    		$-1.25N/AN/ABeat-905.4%
    Mar 21
    		$11.18N/AN/ABeat+305.3%
    Dec 20
    		$-31.93N/AN/ABeat-1407.8%
    Sep 20
    		$0.14N/AN/ABeat+100.1%
    Jun 20
    		$0.16N/AN/ABeat+100.1%
    Mar 20
    		$-5.45N/AN/ABeat+12.4%
    Dec 19
    		$2.44N/AN/ABeat+103.9%
    Sep 19
    		$-146.51N/AN/ABeat-179.4%
    Jun 19
    		$-119.36N/AN/ABeat-37339.6%
    Mar 19
    		$-6.22N/AN/ABeat-302.0%
    Dec 18
    		$-61.93N/AN/ABeat-923.8%
    Sep 18
    		$184.54N/AN/ABeat+9064.4%
    Jun 18
    		$-0.32N/AN/ABeat-333.2%
    Mar 18
    		$-1.55N/AN/ABeat-23.6%
    Dec 17
    		$-6.05N/AN/ABeat-1641.7%
    Sep 17
    		$-2.06N/AN/ABeat-630.0%
    Jun 17
    		$-0.07N/AN/ABeat-
    Mar 17
    		$-1.25N/AN/ABeat-
    Dec 16
    		$-0.35N/AN/ABeat-
    Sep 16
    		$-0.28N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.55EV/EBITDA-1.46x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-208004.00%
    ROE-77.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio12.91xQuick Ratio12.73x
    Trading Statistics
    Beta1.94Avg Volume19.24M
    52-Week High$6.2552-Week Low$0.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.18
    SMA 20$1.15
    SMA 50$1.09
    SMA 200$1.89
    EMA 10$1.16
    EMA 20$1.13
    EMA 50$1.23
    EMA 200$1.90

    MACD

    Line: 0.03Signal: 0.02Hist: 0.00

    ADX

    ADX: 38.4+DI: 34.3-DI: 16.7

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down20.0
    PSAR$1.89

    Bollinger Bands

    Upper Band$1.51
    Lower Band$0.78
    %B Position6395%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    49.8

    Momentum Oscillators

    Stoch %K19.6
    Stoch %D19.2
    Williams %R-81.1
    ROC (10d)2.7%
    Momentum0.03
    CCI (20d)-17.1
    MFI (14d)80.3

    Volatility Measures

    ATR (14d)$0.16(14.1%)
    StdDev (20d)0.18
    Hist Vol284.9%(High)

    Volume Flow

    VWAP$1.14
    OBV564.0M
    AD Line-394.1M
    CMF (20d)-0.519

    Volume Metrics

    Avg Vol (20d)20.2M
    Vol Ratio0.0x(Low)
    VWMA (20d)$1.15

    Pivot Points

    R3$1.24
    R2$1.21
    R1$1.18
    Pivot Point$1.15
    S1$1.11
    S2$1.08
    S3$1.04

    Advanced Oscillators

    TSI4.91
    Ultimate Osc39.2
    KST375.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$3,000$0$0$3,000$3,000$0$8,000$0$3,000$6,000
    Cost of Revenue$0$0$994$0$0$1,200$1,200$0$3,200$0$1,200$2,400
    Gross Profit$0$0$2,006$0$0$1,800$1,800$0$4,800$0$1,800$3,600
    Operating Expenses$1.56M$1.46M$1.95M$1.27M$1.26M$1.66M$1.89M$1.11M$1.63M$1.12M$1.77M$1.55M
    R&D$459,200$541,658$550,077$465,154$501,261$743,304$471,840$581,796$924,749$422,392$349,408$992,722
    SG&A$1.08M$888,640$1.37M$776,821$731,517$888,397$1.39M$498,607$676,086$671,484$1.40M$531,042
    Operating Income$-1,562,163$-1,459,153$-1,945,782$-1,273,034$-1,263,520$-1,660,478$-1,885,734$-1,109,674$-1,625,306$-1,123,147$-1,771,839$-1,543,185
    Interest Income$50,913$55,436$58,108$37,100$30,217$22,381$31,660$69,539$67,578$81,603$93,215$89,233
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-1,511,250$-1,403,717$-1,887,674$-1,235,934$-1,233,303$-1,638,097$-1,854,074$-1,040,135$-1,557,728$-1,041,544$-1,678,574$-1,453,952
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,511,250$-1,403,717$-1,887,674$-1,235,934$-1,233,303$-1,638,097$-1,854,074$-1,040,135$-1,557,728$-1,041,544$-1,678,574$-1,453,952
    EBITDA$-1,542,872$-1,433,925$-1,916,417$-1,241,975$-1,232,778$-1,629,901$-1,863,095$-1,080,403$-1,596,035$-1,093,876$-1,746,318$-1,520,164
    EBIT$-1,562,163$-1,459,153$-1,945,782$-1,273,034$-1,263,520$-1,660,478$-1,885,734$-1,109,674$-1,625,306$-1,123,147$-1,771,839$-1,543,185
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CELZ

    News

    Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

    Creative Medical Technology Holdings has completed enrollment and treatment for its FDA-cleared ADAPT trial, including the opioid cohort, for CELZ-201 / Olastrocel, a regenerative cell therapy for chronic lower back pain. This milestone allows the company to transition to data maturation and regulatory planning, aiming for RMAT evaluation and Phase 3 discussions with the FDA. The completion also reduces active trial expenses, extending the company's operating runway without immediate further fundraising.

    The Manila Times•8/21/26•
    Bullish

    CELZ Looks 171.4% Overvalued on GF Value™

    Creative Medical Technology Holdings Inc (CELZ) is considered 171.4% overvalued according to its GF Value™, despite a Roth Capital analyst reaffirming a Buy rating with a $20 price target due to promising ADAPT trial results. The company exhibits an extremely high Price-to-Sales ratio of 1330x, signaling high investor expectations for future revenue growth, although it currently reports zero revenue and is unprofitable. CELZ's GF Score™ is 28/100, reflecting significant weaknesses in profitability and growth, alongside strong financial health with no debt.

    GuruFocus•8/20/26•
    Bearish

    Creative Medical completes enrollment in chronic back pain trial

    Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) has completed the enrollment and treatment of all patients in its ADAPT clinical trial for CELZ-201 (Olastrocel), an investigational therapy for chronic lower back pain. The trial, which included an FDA-cleared opioid expansion cohort, is evaluating the safety, tolerability, and preliminary efficacy of the perinatal tissue-derived regenerative cell therapy. Interim 180-day data showed significant improvements in functional disability and pain reduction, with no serious adverse events reported.

    Investing.com•8/20/26•
    Bullish

    Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning

    Creative Medical Technology Holdings (NASDAQ: CELZ) announced the completion of enrollment and treatment in its FDA-cleared ADAPT trial for CELZ-201/Olastrocel, including an opioid expansion cohort, aimed at treating chronic lower back pain. The company reported positive interim safety and efficacy data, with significant functional improvement and pain reduction in patients. This milestone allows Creative Medical to transition to data maturation and regulatory planning, aiming for RMAT evaluation and Phase 3 discussions with the FDA, while reducing clinical execution costs and extending its operating runway.

    Stock Titan•8/20/26•
    Somewhat-Bullish

    CELZ Looks 142.9% Overvalued on GF Value™

    Creative Medical Technology Holdings Inc (CELZ) is considered 142.9% overvalued based on GuruFocus' GF Value™ metric, trading at $1.19 per share against an estimated fair value of $0.49. Despite the recent completion of its ADAPT clinical trial for CELZ-201, the company exhibits an extremely high Price-to-Sales ratio of 1190.1x and a low GF Score™ of 28/100, reflecting significant challenges in profitability and growth. While CELZ boasts strong financial strength with no debt, investors are cautioned about its early-stage, high-risk nature and the reliance on future growth expectations that are not yet reflected in revenues or earnings.

    GuruFocus•8/20/26•
    Bearish

    Frequently Asked Questions About CELZ

    Does CELZ pay dividends?
    Creative Medical Technology Holdings Inc (CELZ) does not currently pay a regular dividend.
    What is CELZ's market cap?
    Creative Medical Technology Holdings Inc (CELZ) has a market capitalization of $7.52M with a current stock price of $1.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In